pSivida Corp. to Report Third Quarter Fiscal Year 2017 Financial Results on Thursday, May 4th
April 19 2017 - 4:01PM
pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the
development of sustained release drug delivery products primarily
for treating eye diseases, today announced its financial results
for the third quarter of fiscal year 2017 will be released after
the market close on Thursday, May 4, 2017, followed the same
day by a conference call and live webcast scheduled for 4:30
p.m. ET.
The conference call may be accessed by dialing
(877) 312-7507 from the U.S. and Canada, or (631)
813-4828 from international locations. The conference ID is
7711761. A live webcast will be available on the Investor Relations
section of the corporate website
at http://www.psivida.com.
A replay of the call will be available
beginning May 4, 2017, at approximately 7:30 p.m.
ET and ending on May 11, 2017, at 11:59 p.m. ET. The
replay may be accessed by dialing (855) 859-2056 within
the U.S. and Canada or (404) 537-3406 from
international locations, Conference ID Number: 7711761. A replay of
the webcast will also be available on the corporate website during
that time.
About pSivida Corp. pSivida
Corp. (www.psivida.com), headquartered in Watertown, MA,
is a leader in the development of sustained release drug products
for treating eye diseases. pSivida has developed three of only four
FDA-approved sustained-release treatments for back-of-the-eye
diseases. The most recent, ILUVIEN®, a micro-insert for diabetic
macular edema, licensed to Alimera Sciences, is currently sold
directly in the U.S. and three EU countries. Retisert®, an implant
for posterior uveitis, is licensed to and sold by Bausch &
Lomb. pSivida's lead product candidate, Durasert™ micro-insert for
posterior segment uveitis being independently developed, is
currently in pivotal Phase 3 clinical trials. pSivida's
pre-clinical development program is focused on using its core
platform technology, Durasert™, to deliver drugs to treat wet
age-related macular degeneration, glaucoma, osteoarthritis and
other diseases. To learn more about pSivida please
visit www.psivida.com and connect
on Twitter, LinkedIn, Facebook and Google+.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES
LITIGATION REFORM ACT OF 1995: Various statements made in this
release are forward-looking, and are inherently subject to risks,
uncertainties and potentially inaccurate assumptions. All
statements that address activities, events or developments that we
intend, expect or believe may occur in the future are
forward-looking statements. Some of the factors that could cause
actual results to differ materially from the anticipated results or
other expectations expressed, anticipated or implied in our
forward-looking statements include uncertainties with respect to:
our ability to obtain needed capital; our ability to achieve
profitable operations; potential declines in Retisert royalties;
fluctuations in our operating results; further impairment of our
intangible assets; our ability to obtain marketing approvals for
and successfully commercialize Durasert three-year uveitis for
posterior segment uveitis; performance by CROs, vendors and
investigators; timing of filing marketing approval applications for
Durasert three-year uveitis; acceptability of data to be filed in
support of Durasert three-year uveitis marketing applications;
maintenance of EU orphan designation for Durasert three-year
uveitis, potential off-label sales of ILUVIEN for posterior segment
uveitis; successful commercialization of, and receipt of revenues
from, ILUVIEN for DME; Alimera’s ability to continue as a going
concern; the effect of pricing and reimbursement decisions on sales
of ILUVIEN for DME; consequences of fluocinolone acetonide side
effects; outcome of dispute with Alimera on commercialization
expenses; our ability to develop Tethadur to successfully deliver
large biologic molecules and develop products using it; efficacy
and future development of a severe OA implant by us; our ability to
successfully develop product candidates, initiate and complete
clinical trials and receive regulatory approvals; our ability to
market and sell products; the success of current and future license
agreements; termination or breach of current license agreements;
effects of competition and other developments affecting sales of
products; market acceptance of products; effects of guidelines,
recommendations and studies; protection of intellectual property
and avoiding intellectual property infringement; retention of key
personnel; product liability; industry consolidation; compliance
with environmental laws; manufacturing risks; risks and costs of
international business operations; effects of potential U.K. exit
from the EU; legislative or regulatory changes; volatility of stock
price; possible dilution; absence of dividends; and other factors
described in our filings with the SEC. You should read and
interpret any forward-looking statements in light of these risks.
Should known or unknown risks materialize, or should underlying
assumptions prove inaccurate, actual results could differ
materially from past results and those anticipated, estimated or
projected in the forward-looking statements. You should bear this
in mind as you consider any forward-looking statements. Our
forward-looking statements speak only as of the dates on which they
are made. We do not undertake any obligation to publicly update or
revise our forward-looking statements even if experience or future
changes makes it clear that any projected results expressed or
implied in such statements will not be realized.
Contact:
EVC Group
Michael Polyviou/Doug Sherk – Investors
mpolyviou@evcgroup.com; dsherk@evcgroup.com
212.850.6020; 415.652.9100
Thomas Gibson – Media
tom@tomgibsoncommunications.com
201-476-0322
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Apr 2023 to Apr 2024